197 related articles for article (PubMed ID: 21514072)
21. French multicentre clinical evaluation of helical TomoTherapy for anal cancer in a cohort of 64 consecutive patients.
Vendrely V; Henriques de Figueiredo B; Rio E; Benech J; Belhomme S; Lisbona A; Frison E; Doussau A; Nomikossoff N; Mahé MA; Kantor G; Maire JP
Radiat Oncol; 2015 Aug; 10():170. PubMed ID: 26268888
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of a 36 Gy elective node irradiation dose in anal cancer.
Lépinoy A; Lescut N; Puyraveau M; Caubet M; Boustani J; Lakkis Z; Fantoli M; Buffet-Miny J; Kim S; Bednarek C; Maingon P; Créhange G; Bosset JF
Radiother Oncol; 2015 Aug; 116(2):197-201. PubMed ID: 26277433
[TBL] [Abstract][Full Text] [Related]
23. Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial.
Glynne-Jones R; Sebag-Montefiore D; Meadows HM; Cunningham D; Begum R; Adab F; Benstead K; Harte RJ; Stewart J; Beare S; Hackshaw A; Kadalayil L;
Lancet Oncol; 2017 Mar; 18(3):347-356. PubMed ID: 28209296
[TBL] [Abstract][Full Text] [Related]
24. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
Lv X; Cao X; Xia WX; Liu KY; Qiang MY; Guo L; Qian CN; Cao KJ; Mo HY; Li XM; Li ZH; Han F; He YX; Liu YM; Wu SX; Bai YR; Ke LR; Qiu WZ; Liang H; Liu GY; Miao JJ; Li WZ; Lv SH; Chen X; Zhao C; Xiang YQ; Guo X
Lancet Oncol; 2021 May; 22(5):716-726. PubMed ID: 33857411
[TBL] [Abstract][Full Text] [Related]
25. Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014).
Matzinger O; Roelofsen F; Mineur L; Koswig S; Van Der Steen-Banasik EM; Van Houtte P; Haustermans K; Radosevic-Jelic L; Mueller RP; Maingon P; Collette L; Bosset JF;
Eur J Cancer; 2009 Nov; 45(16):2782-91. PubMed ID: 19643599
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.
Leon O; Guren MG; Radu C; Gunnlaugsson A; Johnsson A
Eur J Cancer; 2015 Dec; 51(18):2740-6. PubMed ID: 26597443
[TBL] [Abstract][Full Text] [Related]
27. EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer.
Glynne-Jones R; Meadows H; Wan S; Gollins S; Leslie M; Levine E; McDonald AC; Myint S; Samuel L; Sebag-Montefiore D;
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):119-26. PubMed ID: 18472366
[TBL] [Abstract][Full Text] [Related]
28. Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy.
Bazan JG; Luxton G; Kozak MM; Anderson EM; Hancock SL; Kapp DS; Kidd EA; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):983-91. PubMed ID: 24161422
[TBL] [Abstract][Full Text] [Related]
29. Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma.
Olivatto LO; Vieira FM; Pereira BV; Victorino AP; Bezerra M; Araujo CM; Erlich F; Faroni L; Castro L; Lusis EC; Marins A; Ferreira CG
Cancer; 2013 Aug; 119(16):2973-80. PubMed ID: 23674135
[TBL] [Abstract][Full Text] [Related]
30. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index.
Hung A; Crane C; Delclos M; Ballo M; Ajani J; Lin E; Feig B; Skibber J; Janjan N
Cancer; 2003 Mar; 97(5):1195-202. PubMed ID: 12599225
[TBL] [Abstract][Full Text] [Related]
31. Prospective phase II study of tomotherapy based chemoradiation treatment for locally advanced anal cancer.
Joseph K; Nijjar Y; Warkentin H; Schiller D; Tankel K; Usmani N; Severin D; Ghosh S; Syme A; Nijjar T; Mulder K; Doll C; Wong C; Field C
Radiother Oncol; 2015 Nov; 117(2):234-9. PubMed ID: 26306677
[TBL] [Abstract][Full Text] [Related]
32. Concomitant chemoradiotherapy with Cisplatin plus 5-Fluorouracil for anal squamous cell carcinoma.
El-Hadaad HA; Wahba HA; Roshdy S
J Gastrointest Cancer; 2015 Jun; 46(2):156-60. PubMed ID: 25810165
[TBL] [Abstract][Full Text] [Related]
33. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy.
Kachnic LA; Tsai HK; Coen JJ; Blaszkowsky LS; Hartshorn K; Kwak EL; Willins JD; Ryan DP; Hong TS
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):153-8. PubMed ID: 21095071
[TBL] [Abstract][Full Text] [Related]
34. Outcomes after intensity-modulated compared with 3-dimensional conformal radiotherapy with chemotherapy for squamous cell carcinoma of the anal canal.
Agarwal MS; Hitchcock KE; Morris CG; George TJ; Mendenhall WM; Zlotecki RA
Curr Oncol; 2019 Aug; 26(4):e515-e521. PubMed ID: 31548820
[TBL] [Abstract][Full Text] [Related]
35. Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281).
Meropol NJ; Niedzwiecki D; Shank B; Colacchio TA; Ellerton J; Valone F; Budinger S; Day JM; Hopkins J; Tepper J; Goldberg RM; Mayer RJ
J Clin Oncol; 2008 Jul; 26(19):3229-34. PubMed ID: 18490648
[TBL] [Abstract][Full Text] [Related]
36. PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer.
Zimmermann M; Beer J; Bodis S; von Moos R; Vlachopoulou V; Zwahlen DR; Oehler C
Acta Oncol; 2017 Dec; 56(12):1734-1740. PubMed ID: 28557585
[TBL] [Abstract][Full Text] [Related]
37. Preliminary results of a phase II study of high-dose radiation therapy and neoadjuvant plus concomitant 5-fluorouracil with CDDP chemotherapy for patients with anal canal cancer: a French cooperative study.
Peiffert D; Seitz JF; Rougier P; François E; Cvitkovic F; Mirabel X; Nasca S; Ducreux M; Hannoun-Levi JM; Lusinchi A; Debrigode E; Conroy T; Pignon JP; Gérard JP
Ann Oncol; 1997 Jun; 8(6):575-81. PubMed ID: 9261527
[TBL] [Abstract][Full Text] [Related]
38. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response.
Kaufman DS; Winter KA; Shipley WU; Heney NM; Chetner MP; Souhami L; Zlotecki RA; Sause WT; True LD
Oncologist; 2000; 5(6):471-6. PubMed ID: 11110598
[TBL] [Abstract][Full Text] [Related]
39. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
[TBL] [Abstract][Full Text] [Related]
40. Multicenter Phase 2 Study of Cisplatin and 5-Fluorouracil With Concurrent Radiation Therapy as an Organ Preservation Approach in Patients With Squamous Cell Carcinoma of the Cervical Esophagus.
Zenda S; Kojima T; Kato K; Izumi S; Ozawa T; Kiyota N; Katada C; Tsushima T; Ito Y; Akimoto T; Hasegawa Y; Kanamaru M; Daiko H
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):976-984. PubMed ID: 27745985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
